Sign in Subscribe
Pharmaceutical industry

GeneThera, Inc. and Johne's Disease Developments Attract Investor Attention

Strategic Insights

— 2 min read

As the financial world anxiously awaits the outcome of the negotiations between GeneThera, Inc. and the Universidad Nacional Autonoma de Mexico (National Autonomous University of Mexico), Wall Street News Alert, a division of Wall Street Capital Funding LLC, has placed aggressive investors on alert to monitor the progress of GeneThera. The company, a molecular biotechnology firm, is on the verge of securing a partnership to develop a test and vaccine for Johne's Disease, a highly contagious and often fatal infection that affects primarily the small intestine of ruminants. With the potential to eradicate Johne's Disease in Mexico, GeneThera's future prospects have sparked significant interest among investors.

Key Takeaways:

  • GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, CO, providing genetic diagnostic solutions for the veterinary and agricultural industries.
  • The company's proprietary diagnostic solution, GEA(TM), is based on a genetic expression assay designed to function on a highly automated Fluorogenic PCR platform.
  • GeneThera is working towards developing tests for Mad Cow Disease, Chronic Wasting Disease, E.Coli 0157:H7, and Johne's Disease, making significant advancements in the fight against these diseases.
  • The company's stock, GTHA, was trading at around Three cents a share prior to the latest press release, indicating potential for significant price increases in the near future.
  • The partnership with the Universidad Nacional Autonoma de Mexico will enable GeneThera to develop a nationwide testing and vaccination program to eradicate Johne's Disease in Mexico.
  • Johne's Disease is a significant problem in Mexico, causing substantial economic losses in the cattle industry.
  • The disease is caused by Mycobacterium avium subspecies paratuberculosis, a hardy bacteria related to the agents of leprosy and tuberculosis.
  • A national study of US dairies found that approximately 22 percent of US dairy farms have at least 10% of the herd infected with Johne's Disease, resulting in significant economic losses for the industry.

Statistics:

  • GeneThera's GEA(TM) technology is designed to function on a highly automated Fluorogenic PCR platform, enabling the company to offer tests that are currently not available from other technologies.
  • The partnership with the Universidad Nacional Autonoma de Mexico has the potential to eradicate Johne's Disease in Mexico, significantly impacting the cattle industry.
  • Approximately 22 percent of US dairy farms have at least 10% of the herd infected with Johne's Disease, resulting in average losses of $40 per cow for herds with low Johne's Disease clinical cull rates and $227 for herds with high Johne's Disease clinical cull rates.
  • GeneThera's stock, GTHA, was trading at around Three cents a share prior to the latest press release, indicating potential for significant price increases in the near future.

Sources:

  • Wall Street News Alert, "GeneThera, Inc. Continues to Make Progress in Development of Test and Vaccine for Johne's Disease," December 15, 2006.
  • GeneThera, Inc. press release, "GeneThera, Inc. Forms New Company in Mexico to Develop and Commercialize Live Animal Test for Johne's Disease," December 14, 2006.
  • University of Wisconsin-Madison, "Johne's Disease," 2006.

Read more